Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Discontinuing oral anticoagulation for elective surgical interventions].

Praxis·2011

Same author

History of tissue factor.

British journal of haematology·2000

Same author

Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5).

British journal of haematology·2000

Same author

[Diagnosis of vitamin B12 deficiency: only apparently child's play].

Schweizerische medizinische Wochenschrift·1999

Same author

[Visceral and neurological complications in Varicella infections of adults].

Schweizerische medizinische Wochenschrift·1996

Same author

[Differential diagnostic aspects of progressive spastic paraplegia in adults with emphasis on neurometabolic diseases].

Praxis·1995

Search research articles

Related Experiment Video

Updated: May 17, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

[New anticoagulants - direct factor Xa-inhibitors].

¹Medizinsche Klinik, Spital Uster. esther.baechli@spitaluster.ch

Therapeutische Umschau. Revue Therapeutique

|November 3, 2012

Summary

Direct oral factor Xa-inhibitors offer effective antithrombotic treatment with improved administration compared to older drugs. While generally safe and efficient, their use requires consideration of renal function and potential drug interactions.

Area of Science:

Pharmacology
Cardiovascular Medicine
Thrombosis Research

Background:

Direct oral anticoagulants (DOACs) targeting Factor Xa are established antithrombotic agents.
Rivaroxaban, apixaban, and edoxaban are currently available DOACs.
Clinical studies have demonstrated the efficacy and safety of these novel oral anticoagulants.

Purpose of the Study:

To review the clinical use, efficacy, and safety of direct oral Factor Xa-inhibitors.
To compare DOACs with traditional anticoagulants like vitamin K antagonists and low-molecular-weight heparins.
To highlight the advantages and disadvantages of DOACs in patient care.

Main Methods:

Review of clinical trial data for rivaroxaban, apixaban, and edoxaban.
Analysis of registered indications in the EU and CH.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: May 17, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Comparison of DOACs with vitamin K antagonists and low-molecular-weight heparins regarding efficacy, safety, and administration.

Main Results:

Rivaroxaban and apixaban have been extensively studied in large patient cohorts (>60,000 patients).
DOACs demonstrate non-inferior or superior outcomes compared to traditional anticoagulants.
DOACs offer simplified dosing (once or twice daily) without the need for laboratory monitoring.

Conclusions:

Direct oral Factor Xa-inhibitors represent a significant advancement in antithrombotic therapy for appropriate patients.
Advantages include improved administration and comparable or superior efficacy.
Disadvantages such as dependence on renal clearance, drug interactions, and lack of a specific antidote require careful patient selection and management.